Table 1.
Patient characteristics
| GP (%) | XP (%) | p-value | |
|---|---|---|---|
| No. of patients | 49 | 44 | |
| Age (yr) | 0.153 | ||
| Median (range) | 62 (45-81) | 65 (39-80) | |
| > 65 | 19 (38.8) | 23 (52.3) | 0.194 |
| > 70 | 7 (14.3) | 9 (20.4) | 0.434 |
| Gender | 0.62 | ||
| Male | 31 (63.3) | 30 (68.2) | |
| Female | 18 (36.7) | 14 (31.8) | |
| Type | 0.196 | ||
| Intrahepatic cholangiocarcinoma | 12 (24.5) | 16 (36.4) | |
| Extrahepatic cholangiocarcinoma | 19 (38.8) | 16 (36.4) | |
| Gallbladder cancer | 18 (36.7) | 12 (27.2) | |
| Disease status | 0.831 | ||
| Recurrent | 20 (40.8) | 14 (70) | |
| Adjuvant treatmenta) | 17 (38.6) | 12 (70.5) | |
| Metastatic | 29 (59.2) | 27 (61.4) | |
| Median no. of cycles (range) | 4(1-8) | 3(1-13) | |
| Treatment termination due to drug intolerance | 3 (6.1) | 12 (27.3) |
GP, gemcitabine-cisplatin; XP, capecitabine-cisplatin.
a)
Adjuvant treatment: fluorouracil (5-FU) chemoradiation and four cycles of 5-FU.